We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Patient Page |

Vitiligo FREE

Sarah Ringold, MD, Writer; Tiffany J. Glass, MA, Illustrator; Richard M. Glass, MD, Editor
JAMA. 2005;293(6):762. doi:10.1001/jama.293.6.762.
Text Size: A A A
Published online

Vitiligo is a disorder that results in damage to and loss of melanocytes (cells within the skin that produce melanin, the skin's natural color or pigment). This damage results in patches of depigmented skin. The process primarily affects the skin, but may also affect pigmentation of other sites, including the eyes and hair. Vitiligo may be focal (occurring in only a few patches), segmental (in which the patches occur on one side of the body only), and generalized (patches throughout the body). The course of vitiligo varies and some patients may develop only a few patches while others may experience almost total depigmentation. Vitiligo may affect persons of all ages; however, its onset most commonly occurs during young adulthood. The cause of vitiligo is not completely understood; however, it is thought to be an autoimmune process (a process by which the body produces an immune response against some of its own cells, in this case melanocytes, resulting in their destruction). The February 9, 2005, issue of JAMA includes an article that describes the disorder and discusses available treatments.


In addition to obtaining a complete medical history and performing a physical examination, including a detailed skin examination, your doctor may order blood tests and refer you to a dermatologist (a doctor with specialized training in skin disorders). A skin biopsy (removal of a small area of the affected skin for testing) may be done to confirm the diagnosis. Because there is evidence that people with vitiligo are at an increased risk for other autoimmune disorders, in particular disorders of the thyroid gland (the gland in the neck that produces a hormone that controls many important processes within the body), your doctor may choose to evaluate you periodically for these disorders.


Treatment may not be necessary in limited cases or when the patches are not a concern for the patient.

  • Topical treatments are creams or ointments that are applied to affected areas of the skin and block the immune system within these areas, decreasing melanocyte damage.

  • Phototherapy (the use of ultraviolet light or laser therapies) targets the affected areas with specific wavelengths of light.

  • Surgical therapies, involving the transplantation of a patch of normal skin or melanocytes grown in culture into an area of depigmentation, may be appropriate for certain kinds of focal vitiligo.

  • In many cases, optimal treatment may require a combination of these therapies.



To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA's Web site at http://www.jama.com.

Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases

The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. Any other print or online reproduction is subject to AMA approval. To purchase bulk reprints, call 718/946-7424.




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Collections
PubMed Articles
Vitiligo co-existing with lichen striatus: more than a coincidence? J Eur Acad Dermatol Venereol Published online Aug 31, 2016;
Nail abnormalities in patients with vitiligo. An Bras Dermatol ;91(4):442-445.